

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	2
-------	---	----	---

APPLICATION NO.: 10/643,141

ATTY. DOCKET NO.: C1037.70049US00

FILING DATE: August 18, 2003

CONFIRMATION NO.: 3287

APPLICANT: Stephen L. Hutcherson et al.

GROUP ART UNIT: 1643

EXAMINER: APR 20 2009 Anne Gussow

## U.S. PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/AMG/		5,194,428		Agrawal et al.	03-16-1993
		7,271,156	B2	Krieg et al.	07-18-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		7,488,490	B2	Davis et al.	02-10-2009
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0226649	A1	Schetter et al.	09-18-2008
		2009-0017021	A1	Davis et al.	01-15-2009
/AMG/		2009-0060927	A1	Wagner et al.	03-05-2009

## FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
/AMG/		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
		WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
		WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	
/AMG/		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/AMG/		[No Author Listed] "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy," Press Release, Wellesley, MA, 2007 Jan 22/PRNewswire-FirstCall—Coley Pharmaceutical Group, Inc.	

EXAMINER:

/Anne M. Gussow/

DATE CONSIDERED:

06/10/2009

<sup>#</sup> EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 2 of 2

APPLICATION NO.: 10/643,141	ATTY. DOCKET NO.: C1037.70049US00
FILING DATE: August 18, 2003	CONFIRMATION NO.: 3287
APPLICANT: Stephen L. Hutcherson et al.	
GROUP ART UNIT: 1643	EXAMINER: Anne Gussow

/AMG/	Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".
	AHLUWALIA et al., Immunostimulatory profiles from two classes of CpG ODN administered subcutaneously to healthy subjects. ICI FOCIS 2004. Poster.
	KRIEG, Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7. Review.
	MCHUTCHISON et al., Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response. 41 <sup>st</sup> Meeting of the European Association for the Study of Liver Diseases. April 26-30, 2006. Vienna, Austria. 8 pages.
	MCHUTCHISON et al., Phase 1B Study Shows Toll-Like Receptor 9 Agonist CPG 10101 Decreases HCV RNA in Patients with Chronic Hepatitis C. 58 <sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases. November 2-6, 2007. Boston, MA. 2 pages.
	READETT et al., PF-3512676 (CPG7909) a Toll-like receptor 9 agonist – status of development for non-small cell lung cancer (NSCLC). Abstract PD3-1-6. Pfizer. 24 Aug. 2007. Poster.
	VICARI et al., Development of targeted toll-like receptor agonists for cancer therapy. PPO Focus. 2007; 1(2):1-15.
	VICARI et al., Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother. 2009 Apr;58(4):615-28. Epub 2008 Sep 19.
	VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and hlg IFN-alpha secretion from PBMC of HCV chronic carriers. Antiv Ther. 2002;7:L115.
/AMG/	VOLLMER, TLR9 in health and disease. Int Rev Immunol. 2006 May-Aug;25(3-4):155-81.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:

/Anne M. Gussow/

DATE CONSIDERED:

06/10/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.